[Form 4] 908 Devices Inc. Insider Trading Activity

Rhea-AI Filing Summary

908 Devices Inc. director Keith Crandell reported equity compensation activity and a derivative exercise. On June 11, 2026, he received a stock option grant for 6,209 shares of Common Stock at an exercise price of $8.22 per share, vesting in equal monthly installments over 12 months, and a grant of 13,656 Restricted Stock Units (RSUs) that vest in full on June 11, 2027 or the day prior to the 2027 annual meeting, subject to continued service and prorating on earlier termination. On June 10, 2026, 14,083 RSUs became fully vested and were converted into 14,083 shares of Common Stock, leaving 39,374 shares of Common Stock held directly after the transaction. An entity, ARCH Venture Fund VII, L.P., associated through layered general partners with Crandell as a managing director, holds 5,725,045 shares of Common Stock indirectly; he may be deemed to beneficially own these securities but disclaims beneficial ownership except to the extent of his pecuniary interest.

Insider Trade Summary

14,083 shares exercised/converted

Mixed 5 txns

Insider CRANDELL KEITH

Role null

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	13,656	$0.00	--
Grant/Award	Stock Option (option to buy)	6,209	$0.00	--
Exercise	Restricted Stock Units	14,083	$0.00	--
Exercise	Common Stock	14,083	$0.00	--
holding	Common Stock	--	--	--

Holdings After Transaction: Restricted Stock Units — 13,656 shares (Direct, null); Stock Option (option to buy) — 6,209 shares (Direct, null); Common Stock — 39,374 shares (Direct, null); Common Stock — 5,725,045 shares (Indirect, See footnote)

Footnotes (1)

1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.001, when vested. The securities are owned directly by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the securities held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the securities held by ARCH Fund VII. The reporting person is a managing director of ARCH VII LLC, and may be deemed to beneficially own the securities held by ARCH Fund VII. The reporting person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. The RSUs became fully vested on June 10, 2026, the day prior to the 2026 Annual Meeting of the Stockholders of 908 Devices Inc. The RSUs have no expiration date. The RSUs become fully vested on June 11, 2027 or the day prior to the 2027 Annual Meeting of the Stockholders of 908 Devices Inc., whichever occurs first, subject to the reporting person's continued service through the applicable vesting date, provided that, if the reporting person terminates their service for any reason, then a prorated number of RSUs will vest. The RSUs have no expiration date. The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following June 11, 2026, subject to the reporting person's continued service through the applicable vesting date.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CRANDELL KEITH

(Last) (First) (Middle)

8755 W. HIGGINS ROAD

SUITE 1025

(Street)

CHICAGO ILLINOIS 60631

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
908 Devices Inc. [ MASS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/10/2026		M		14,083	A	(1)	39,374	D
Common Stock								5,725,045	I	See footnote(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	06/10/2026		M			14,083	(3)	(3)	Common Stock	14,083	$0	0	D
Restricted Stock Units	(1)	06/11/2026		A		13,656		(4)	(4)	Common Stock	13,656	$0	13,656	D
Stock Option (option to buy)	$8.22	06/11/2026		A		6,209		(5)	06/10/2036	Common Stock	6,209	$0	6,209	D

Explanation of Responses:

1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.001, when vested.

2. The securities are owned directly by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the securities held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the securities held by ARCH Fund VII. The reporting person is a managing director of ARCH VII LLC, and may be deemed to beneficially own the securities held by ARCH Fund VII. The reporting person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein.

3. The RSUs became fully vested on June 10, 2026, the day prior to the 2026 Annual Meeting of the Stockholders of 908 Devices Inc. The RSUs have no expiration date.

4. The RSUs become fully vested on June 11, 2027 or the day prior to the 2027 Annual Meeting of the Stockholders of 908 Devices Inc., whichever occurs first, subject to the reporting person's continued service through the applicable vesting date, provided that, if the reporting person terminates their service for any reason, then a prorated number of RSUs will vest. The RSUs have no expiration date.

5. The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following June 11, 2026, subject to the reporting person's continued service through the applicable vesting date.

	/s/ Mark S. Levine, Attorney-in-Fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What equity awards did 908 Devices (MASS) director Keith Crandell receive?

Keith Crandell received a stock option grant for 6,209 shares at an exercise price of $8.22, plus 13,656 RSUs. The RSUs vest in full on June 11, 2027 or the day before the 2027 annual meeting, subject to continued service and prorating on early departure.

How many 908 Devices (MASS) RSUs vested for Keith Crandell in June 2026?

On June 10, 2026, 14,083 RSUs for Keith Crandell became fully vested and converted into 14,083 shares of Common Stock. These RSUs had no expiration date and vested the day prior to the 2026 annual stockholders’ meeting of 908 Devices Inc.

What are Keith Crandell’s direct common share holdings in 908 Devices (MASS) after these transactions?

Following the June 10, 2026 RSU conversion, Keith Crandell holds 39,374 shares of 908 Devices Common Stock directly. This reflects the shares received from vested RSUs along with his existing direct holdings as reported in the Form 4 filing.

How many 908 Devices (MASS) shares are held indirectly through ARCH Venture Fund VII?

An entity, ARCH Venture Fund VII, L.P., holds 5,725,045 shares of 908 Devices Common Stock indirectly. Through general partner entities, Crandell may be deemed a beneficial owner but disclaims beneficial ownership except to the extent of his pecuniary interest in the fund.

What are the vesting terms of Keith Crandell’s June 11, 2026 stock option grant at 908 Devices (MASS)?

The June 11, 2026 option grant for 6,209 shares at $8.22 per share vests and becomes exercisable in substantially equal monthly installments over the 12 months following June 11, 2026, contingent on Crandell’s continued service through each applicable vesting date.

When do Keith Crandell’s new RSUs at 908 Devices (MASS) vest and how are they treated on termination?

The 13,656 RSUs granted June 11, 2026 vest fully on June 11, 2027 or the day before the 2027 annual meeting. Vesting requires continued service, but if service ends earlier, a prorated number of RSUs will vest. These RSUs have no expiration date.